论文部分内容阅读
最近在意大意罗马召开了“欧盟胃肠道疾病周”会议,集中讨论了在依赖类固醇的活动性节段性回肠炎患者中对一种类似人体抗肿瘤坏死因子(TNF)α的单克隆抗体CDP571进行首次随机试验的情况。细胞技术公司报告的结果表明,在一项Ⅱb期的研究中,类固醇依赖性病人停止使用类固醇16周后,44％接受CDP571的病人和22％接受安慰剂对照的病人没有突然发作。在一项单独的试验中,有54％接受CDP571治疗的活动性节段性回肠炎患者在2周时达到临床反应,而安慰剂组仅有26％。
A recent European Conference on Gastrointestinal Diseases Week has been held in Rome, focusing on the discovery of a monoclonal antibody CDP571 similar to human anti-tumor necrosis factor (TNF) alpha in steroid-dependent patients with active Crohn’s disease The first randomized trial was conducted. The results reported by CellTechnology showed that in a Phase IIb study, no steroid-dependent patients discontinued steroid 16 weeks later, and 44% of patients receiving CDP571 and 22% of those receiving placebo did not have a sudden attack. In a separate trial, 54% of patients with active Crohn’s disease treated with CDP571 achieved clinical response at 2 weeks compared with 26% in the placebo group.